Iron deficiency may blunt vaccine protection, study suggests
NCT ID NCT04915820
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether iron deficiency anemia makes COVID-19 vaccines less effective in young women. Researchers gave intravenous iron to 121 participants and measured their immune responses. The goal was to see if correcting iron deficiency could boost vaccine protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- intravenous iron (ferric carboxymaltose)
- What this could lead to
- If iron deficiency is shown to weaken vaccine response, treating it could improve vaccine effectiveness in vulnerable populations.
- What could go wrong
- This is a small, completed observational study without a control group. Results may not apply broadly, and iron treatment carries rare risks like allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Msambweni County Referral Hospital
Msambweni, Kwale County, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?